tert-butyl (2-(2-(2-tetradecanamidoethoxy)ethoxy)ethyl)carbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 甲亚胺酸及其衍生物
• 英文名称: tert-butyl (2-(2-(2-tetradecanamidoethoxy)ethoxy)ethyl)carbamate
• 英文别名: tert-butyl N-[2-[2-[2-(tetradecanoylamino)ethoxy]ethoxy]ethyl]carbamate
• 化学式: C₂₅H₅₀N₂O₅
• 分子量: 458.682
• InChiKey: RGHYYEXXVZTDLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  32
• 可旋转键数：
  23
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  85.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl (2-(2-(2-tetradecanamidoethoxy)ethoxy)ethyl)carbamate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 NH2-EO2-C14
  参考文献：
  名称：

  Engineering a Potent, Long-Acting, and Periphery-Restricted Oxytocin Receptor Agonist with Anorexigenic and Body Weight Reducing Effects

  摘要：

  The effects of oxytocin on food intake and body weight reduction have been demonstrated in both animal models and human clinical studies. Despite being efficacious, oxytocin is enzymatically unstable and thus considered to be unsuitable for long-term use in patients with obesity. Herein, a series of oxytocin derivatives were engineered through conjugation with fatty acid moieties that are known to exhibit high binding affinities to serum albumin. One analog (OT-12) in particular was shown to be a potent full agonist at the oxytocin receptor (OTR) in vitro with good selectivity and long half-life (24 h) in mice. Furthermore, OT-12 is peripherally restricted, with very limited brain exposure (1/190 of the plasma level). In a diet-induced obesity mouse model, daily subcutaneous administration of OT-12 exhibited more potent anorexigenic and body weight reducing effects than carbetocin. Thus, our results suggest that the long-acting, peripherally restricted OTR agonist may offer potential therapeutic benefits for obesity.

  DOI：

  10.1021/acs.jmedchem.9b01862
• 作为产物：
  描述：

  肉豆蔻酸 、 2-(2-(2-氨基乙氧基)乙氧基)乙基氨基甲酸叔丁酯 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 以90%的产率得到tert-butyl (2-(2-(2-tetradecanamidoethoxy)ethoxy)ethyl)carbamate
  参考文献：
  名称：

  [EN] PEPTIDE CONJUGATES AND METHODS OF USE
  [FR] CONJUGUÉS PEPTIDIQUES ET MÉTHODES D'UTILISATION

  摘要：

  本文披露了包括以下内容的肽共轭物：选择自可调节PYY受体的肽、可调节GLP-1受体和GCG受体的肽、可调节GLP-1受体和GIP受体的肽、以及可调节GLP-1受体的肽；以及连接到肽的稳定剂，在第一个氨基酸和第二个氨基酸处连接。还提供了包括催乳素释放肽的肽共轭物。这些肽共轭物可用于治疗肥胖等疾病。此外，还提供了稳定的催乳素释放肽。

  公开号：

  WO2021113535A1

文献信息

• [EN] MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF<br/>[FR] AGENTS THÉRAPEUTIQUES MODIFIÉS ET COMPOSITIONS DE CEUX-CI
  申请人：CALIFORNIA INST BIOMEDICAL RES

  公开号：WO2015038938A1

  公开（公告）日：2015-03-19

  Methods and compositions are provided for extending the half-life of a therapeutic agent. One or more half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modified therapeutic agents (mTAs) comprising one or more half-life extending moieties attached to a therapeutic agent may be used to treat a disease or condition in a subject in need thereof.

  提供了一种延长治疗剂半衰期的方法和组合物。可以将一个或多个延长半衰期的基团连接到治疗剂上，从而延长治疗剂的半衰期。含有一个或多个连接到治疗剂上的延长半衰期基团的改良治疗剂（mTAs）可用于治疗需要的患者的疾病或状况。
• [EN] PEPTIDE CONJUGATES AND METHODS OF USE<br/>[FR] CONJUGUÉS PEPTIDIQUES ET MÉTHODES D'UTILISATION
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2021113535A1

  公开（公告）日：2021-06-10

  Peptide conjugates comprising a peptide selected from a peptide that modulates the PYY receptor, a peptide that modulates both the GLP-1 receptor and the GCG receptor, a peptide that modulates both the GLP-1 receptor and the GIP receptor, and a peptide that modulates the GLP-1 receptor; and a staple attached to the peptide at a first amino acid and a second amino acid are disclosed herein. Also provided are peptide conjugates comprising prolactin-releasing peptide. The peptide conjugates may be used for treating conditions such as obesity. Further provided are stapled prolactin-releasing peptide.

  本文披露了包括以下内容的肽共轭物：选择自可调节PYY受体的肽、可调节GLP-1受体和GCG受体的肽、可调节GLP-1受体和GIP受体的肽、以及可调节GLP-1受体的肽；以及连接到肽的稳定剂，在第一个氨基酸和第二个氨基酸处连接。还提供了包括催乳素释放肽的肽共轭物。这些肽共轭物可用于治疗肥胖等疾病。此外，还提供了稳定的催乳素释放肽。
• [EN] OXYTOCIN DERIVATIVES WITH IMPROVED PROPERTIES<br/>[FR] DÉRIVÉS D'OCYTOCINE AYANT DES PROPRIÉTÉS AMÉLIORÉES
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2021126990A1

  公开（公告）日：2021-06-24

  The present invention provides novel oxytocin derivative compounds that contain a fatty acid moiety that is conjugated to a modified oxytocin scaffold. The oxytocin derivative compounds of the invention are potent oxytocin agonists with substantially improved stability. Also provided in the invention are therapeutic methods of using the compounds in the treatment of various diseases, e.g., metabolic disorders such as obesity.

  本发明提供了一种新型催产素衍生物化合物，其中含有与修改后的催产素骨架共轭的脂肪酸基团。本发明的催产素衍生物化合物是有效的催产素激动剂，并具有显著改善的稳定性。本发明还提供了使用这些化合物治疗各种疾病的治疗方法，例如代谢性疾病，如肥胖症。
• [EN] LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE<br/>[FR] CONJUGUÉS PEPTIDIQUES DOUBLE GIP/GLP-1 À ACTION PROLONGÉE ET PROCÉDÉS D'UTILISATION
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2022257979A1

  公开（公告）日：2022-12-15

  Provided herein are peptides and peptide conjugates comprising a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The peptides may be used for blood glucose management and treating conditions such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

  本文提供了含有双重葡萄糖依赖性胰岛素促泌肽（GIP）和GLP-1受体激动剂的肽和肽共轭物。这些肽可以用于血糖管理和治疗糖尿病、肥胖症、非酒精性脂肪肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）等疾病。
• Modified therapeutic agents and compositions thereof
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US10987427B2

  公开（公告）日：2021-04-27

  Methods and compositions are provided for extending the half-life of a therapeutic agent. One or more half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modified therapeutic agents (mTAs) comprising one or more half-life extending moieties attached to a therapeutic agent may be used to treat a disease or condition in a subject in need thereof.

  本文提供了延长治疗剂半衰期的方法和组合物。可将一个或多个延长半衰期的分子连接到治疗剂上，从而延长治疗剂的半衰期。包含连接到治疗剂上的一个或多个半衰期延长分子的改良治疗剂（mTAs）可用于治疗有需要的受试者的疾病或病症。